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Abstract Angiogenesis is considered a promising target
in the treatment of cancer. Most of the angiogenesis
inhibitors in late-stage clinical testing or approved for the
treatment of cancer act indirectly on endothelial cells. They
either neutralize angiogenic growth factors from the cir-
culation or block the signaling pathways activated by these
growth factors. Another group of angiogenesis inhibitors
are the direct angiostatic compounds. These agents have a
direct effect on the endothelium, affecting cellular regula-
tory pathways, independently of the tumor cells. The
reason that this category of agents is lagging behind
regarding their translation to the clinic may be the lack of
sufficient knowledge on the mechanism of action of these
compounds. The transcription factor NF-jB has been
recently connected with multiple aspects of angiogenesis.
In addition, several recent studies report that angiogenesis
inhibition is associated to NF-jB activation. This is of
special interest since in tumor cells NF-jB activation has
been associated to inhibition of apoptosis and currently
novel treatment strategies are being developed based on
inhibition of NF-jB. The paradigm that systemic NF-jB
inhibition can serve as an anti-cancer strategy, therefore,
might need to be re-evaluated. Based on recent data, it
might be speculated that NF-jB activation, when per-
formed specifically in endothelial cells, could be an
efficient strategy for the treatment of cancer.
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Introduction
The NF-jB/Rel proteins are a family of transcription fac-
tors that include five proteins, p50, p52, p65 or RelA, RelB,
and c-Rel, that exist as homo- and hetero-dimers. The most
common NF-jB heterodimer is composed of p50 and p65.
In resting cells, NF-jB is mainly sequestered in the cyto-
plasm by its association with proteins belonging to the IjB
inhibitor family. Stimuli such as the proinflammatory
cytokines tumor necrosis factor (TNF)-a, and interleukin-1
(IL-1), or bacterial products such as lipopolysaccharide
(LPS) can activate NF-jB. In the canonical pathway, these
stimuli activate IjB kinases (IKKs), which in turn phos-
phorylate the main NF-jB inhibitor, IjBa. This
phosphorylation step leads to the ubiquitination and sub-
sequent degradation by the proteasome of IjBa. The NF-
jB complex translocates to the nucleus where it binds to
jB enhancers present in the regulatory regions of various
genes and where it activates transcription [1]. The NF-jB
target genes are involved in a wide range of biological
functions including proliferation, survival, and inflamma-
tion (Fig. 1).
NF-jB activation has been connected with multiple
aspects of oncogenesis, including the control of tumor cell
proliferation, migration, cell cycle progression, and inhi-
bition of apoptosis [2–4]. Indeed, NF-jB is constitutively
activated in several types of cancer cells and it is
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generally regarded as an anti-apoptotic and pro-oncogenic
signal. The most studied and well-established functions
of NF-jB in promoting oncogenesis are its ability to
(i) induce growth promoting genes such as cyclin D1 and
c-myc and (ii) induce anti-apoptotic genes such as c-IAP-
1, c-IAP-2, or XIAP [3]. Therefore, activation of NF-jB in
cancer cells by chemotherapy or radiation therapy is often
associated with the acquisition of resistance to apoptosis.
This has emerged as a significant impediment to effec-
tive cancer treatment. In combination with chemotherapy,
inhibitors of the NF-jB pathway (e.g., proteasome inhibi-
tors) were recently used with success as treatment against
cancer [5]. Next to this direct effect, it has also been reported
that NF-jB activity can be tumorigenic by activation of
pro-angiogenesis genes, such as VEGF, IL-8, and MMP-9
[6].
In contrast to the negative effects of NF-jB activa-
tion, recent reports suggest that in certain situations
NF-jB can promote apoptosis and may be viewed as a
tumor suppressor gene. For example, blockade of NF-jB
predisposes murine skin to squamous cell carcinoma [7].
This observation could be explained by the fact that in
normal human epidermal cells, NF-jB activation induces
cell cycle arrest [8]. In addition, Ryan et al. describe the
role of NF-jB in p53-mediated programmed cell death.
The tumor suppressor p53 inhibits cell growth through
activation of apoptosis and cell cycle arrest. Using a
p53-inducible Saos-2 cell line, it was demonstrated that
induction of p53 causes activation of NF-jB. Further-
more, inhibition of NF-jB abrogated p53-induced
apoptosis demonstrating that inhibition of NF-jB in
tumors that retain wild-type p53 may reduce a thera-
peutic response [9]. Loss of p65 can also cause
resistance to different agents that induce apoptosis
through p53 [10]. Independently, it was demonstrated
that activation of NF-jB is essential for the cytotoxic
effect of doxorubicin and its analogs [11]. Many
hypotheses have been put forward to explain this dual
activity. The overall conclusion that is emerging is that
the final outcome of NF-jB activation depends on cell
type, the stimulus, and the context of activation [12–14].
The dual activity of NF-jB complicates the systemic use
of broad spectrum NF-jB inhibitors for the treatment of
cancer and it has been suggested to design better ther-
apeutics that specifically unleash the pro-apoptotic
activity of NF-jB [15, 16].
NF-jB in ongoing angiogenesis
NF-jB signaling has been found to regulate endothelial
cell integrity and vascular homeostasis in vivo. Treat-
ment of zebrafish embryos with NF-jB inhibitors
provokes vascular leakage and alters vessel morphology
[17]. The role of NF-jB signaling in tumor angiogenesis
has also been recently investigated. Inoculated tumors
grow faster in transgenic mice expressing mutated IjBa,
under control of the Tie-2 promoter, resulting in endo-
thelial repression of NF-jB [18]. Histological analysis
revealed a striking increase in tumor vascularization in
these mice. This study highlighted, for the first time, the
in vivo role of NF-jB in tumor angiogenesis, indicating
an inhibitory role for NF-jB in tumor angiogenesis.
Based on this study, NF-jB activation in endothelial
cells appears to be a way to block angiogenesis. How-
ever, it is unknown how specific activation of NF-jB in
endothelial cells can be realized and through which
mechanisms NF-jB activation leads to inhibition of
angiogenesis.
Angiogenesis occurs in a coordinated series of steps,
which can be divided into a destabilization, a proliferation,
and a maturation phase. Whereas inhibition of angiogenesis
Fig. 1 Schematic NF-jB pathway. In the canonical activation
pathway, NF-jB (often the dimer composed of p50/p65) is seques-
tered by its main inhibitor IjB-a. Upon stimulation, cell surface
receptors activate IKK complex, which then phosphorylate IjB-a.
These phosphorylations lead to its degradation by the proteasome and
the entry of NF-jB in the nucleus, which turns on target genes
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can prevent diseases with excessive vessel growth such as
cancer, diabetes retinopathy, and arthritis, stimulation of
angiogenesis would be beneficial in the treatment of dis-
eases such as coronary artery disease and critical limb
ischemia in diabetes [19]. One of earliest events in angi-
ogenesis is the degradation of the vascular basement
membrane and the remodeling of the extracellular matrix
(ECM). The role of NF-jB in the regulation of these sys-
tems is well documented. In line with a pro-oncogenic
activity, NF-jB promotes expression of several matrix
metalloproteinases (MMPs), including MMP-2, -3, and -9
[20–22]. However, NF-jB could also inhibit endothelial
cell migration via the up-regulation of tissue inhibitors of
metalloproteinase-1 (TIMP-1) as described in astrocytes
[23]. Next to the MMPs, plasmin is a broad-spectrum
protease that also hydrolyzes many extracellular proteins,
the most notable of which is fibrin. Plasmin is produced
from an inactive precursor called plasminogen. uPA
(urokinase plaminogen activator) and tPA (tissue-type
plasminogen activator) are two proteases with high affinity
for plasminogen. The activation of plasminogen into
plasmin could be negatively regulated by the physiological
inhibitors, namely plasminogen activator inhibitor (PAI)-1
and -2 [24]. In endothelial cells, it has been described for
both reactive oxygen species as well as for TNF-a induced
expression of PAI-1 via NF-jB [25]. In addition, activation
of NF-jB by TNF-a can also lead to the inhibition of the
tPA expression [26]. These data suggest that NF-jB acti-
vation could impair angiogenesis via a decrease in ECM
degradation capacity.
Integrins are the principle adhesion receptors used by
endothelial cells to interact with the extracellular envi-
ronment and are necessary for cell migration, proliferation,
and survival [27]. It has recently been demonstrated that
the interaction of aVb3-integrin with the ECM activates
NF-jB by activation of the IKK complex and degradation
of IjB-a. This activation triggers a pro-survival signal for
example in rat aortic endothelial cells [28].
Many soluble molecules control the balance between
cell proliferation and cell death. While angiogenic factors
such as VEGF and bFGF are mitogenic and act as sur-
vival factors, angiostatic agents induce cell cycle arrest
and promote endothelial cell death [29]. Activation of
NF-jB in endothelial cell leads to the expression of
angiogenic and angiostatic factors. VEGF expression is
up-regulated by hypoxia-induced mitogenic factor through
activation of the NF-jB pathway [30]. On the contrary,
vascular endothelial growth inhibitor (VEGI, reported to
inhibit endothelial cell proliferation) has also been found
to be induced by NF-jB [31]. In addition, the promoters
of thrombospondin-1 and -2, which are among the first
naturally occurring angiostatic agents discovered, contain
NF-jB binding sites [32].
The role of NF-jB in the cell cycle progression has been
also investigated [33]. NF-jB induces expression of acti-
vators of the cell cycle such as cyclin D or -E [34] as well
as expression of inhibitors such as p21/cip1 [35] demon-
strating that the overall effect of NF-jB on cell
proliferation is difficult to predict. To our knowledge, there
are no reports on a direct relationship between NF-jB
activation and proliferation in endothelial cells.
Programmed cell death or apoptosis occurs mainly by
two connected pathways. The extrinsic pathway involves
activation of caspase-8 by cell surface death receptors,
while the intrinsic pathway, involves cytochrome-c release
from mitochondria and subsequent caspase-9 activation. As
previously described for tumor cells, diverse activities have
been observed in endothelial cells. Silibinin, a cancer
chemopreventive agent, was found to induce apoptosis in
endothelial cell line by inhibiting NF-jB [36] and a report
describes that pro-survival effect of VEGF is mediated by
NF-jB activation [37]. However, a large body of evidence
exists that NF-jB activation plays a pro-apoptotic role in
endothelial cells. A high concentration of glucose activates
the production of reactive oxygen species and induces
caspase-3 activation in endothelial cells [38]. Recently, it
has been demonstrated that this is mediated via NF-jB and
subsequent c-Jun N-terminal protein kinase activation [39].
In human cardiac microvascular endothelial cells, IL-18
induces activation of both the intrinsic and extrinsic
apoptotic pathways via NF-jB activation [40]. Angio-
poietin-1 inhibits endothelial cell apoptosis induced by
growth factor deprivation. This effect is mediated via the
activation of an endogenous inhibitor of NF-jB, namely
A20 binding inhibitor of NF-jB (ABIN-2) [41]. In addi-
tion, in endothelial cells, it was observed that A20
inhibition and subsequent activation of NF-jB, effectively
leads to reduced tube formation in a matrigel assay [42].
A role for NF-jB in angiostatic therapy?
The observations described above indicate that NF-jB is
involved in the regulation of migration and/or proliferation/
survival of endothelial cells and suggest a strong link
between NF-jB in angiostatic agent signaling. The fol-
lowing section will highlight the role of NF-jB in the
angiostatic agent signaling. Indeed, several angiostatic
compounds, already described to block tumor growth, have
been reported to act on endothelial cells via NF-jB acti-
vation [29].
Platelet factor-4 (PF4) is an a-chemokine naturally
secreted by platelets and is known to inhibit angiogenesis
[43]. PF4 promotes the expression of E-Selectin in HU-
VEC. Data provide direct evidence that the NF-jB–binding
site is required for PF4-mediated activation of the
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E-selectin promoter. In addition, EMSA experiments
demonstrate that PF4 treatment of HUVECs results in
binding of NF-jB to the E-Selectin promoter already after
1 hour of stimulation [44]. The angiostatic properties of
angiostatin, a cleavage product of plasminogen, have also
been linked with NF-jB. Chen et al. have analyzed the
global action of angiostatin in endothelial cells. By
microarray screening, they have found an altered expres-
sion of 189 genes after treatment with angiostatin. These
genes are mainly involved not only in growth, apoptosis,
migration but also in inflammation [45]. Even though no
direct evidence points a role of NF-jB, angiostatin pro-
motes mRNA expression of RelB as well as many NF-jB
target genes, namely E-selectin, intracellular adhesion
molecule-1 (ICAM-1), Cyclin D1, p21/cip1, and FasL (for
the complete list of altered gene expression, see reference
[45]). Based on these data, there is a strong suggestion that
NF-jB is also activated by angiostatin. The 16 kDa N-
terminal fragment of prolactin (16 K PRL) is a potent an-
giostatic agent in various in vivo models and has been
shown to inhibit endothelial cell migration and prolifera-
tion [46–48]. We have demonstrated that NF-jB activation
is required for 16 K hPRL-induced caspase-8 and -9 acti-
vation and subsequent apoptosis [49]. In addition, it is
interesting to note that NF-jB activation appears to be a
very proximal event. The angiostatic agent Neovastat,
which is currently in phase III clinical studies, inhibits
angiogenesis through an increase in tPA activity and it has
been shown that this induction is NF-jB dependent [50].
Finally, administration of statins has been shown to
decrease tumor growth and angiogenesis [51]. Statins up-
regulate the expression of endothelial and inducible nitric
oxide synthase through NF-jB activation [52].
Based on all these reports, it is suggested that the
activity of angiostatic compounds is dependent on activa-
tion of NF-jB. Therefore, activation of NF-jB specifically
in endothelial cells might be an attractive therapy. TNF-a is
one of the most potent NF-jB activators. The clinical use
of TNF-a as an anti-cancer drug is limited to local treat-
ment (e.g., isolated limb perfusion) because of its systemic
toxicity [53]. To circumvent this problem, targeted delivery
of TNF-alpha to tumor vessels was achieved by coupling
this cytokine with cyclic CNGRC peptide, an aminopep-
tidase N (CD13) ligand that targets the tumor
neovasculature. Administration of this compound leads to a
reduced toxicity, a marked endothelial cell apoptosis,
destruction of blood vessels, and improvement of the anti-
tumor activity of doxorubicin [54]. These studies indicate
that NF-jB activation, specifically in endothelial cells, can
be an efficient strategy for the treatment of cancer.
In conclusion, while in tumor cells NF-jB is mostly
described as an oncogenic factor, up-regulation of NF-jB
in endothelial cells is associated with angiostatic activity. It
might therefore be warranted to revisit anti-cancer thera-
pies based on inhibition of NF-jB activity for effects on
angiogenesis.
An indirect anti-tumor activity of NF-jB through
circumvention of endothelial cell anergy
Next to a direct anti-tumor activity of NF-jB through
inhibition of tumor angiogenesis, the activation of NF-jB
could also be connected with an indirect anti-tumor activity
through reversal of endothelial unresponsiveness to
inflammatory signals, a process called endothelial cell
anergy. The latter is defined as the inability of tumor
endothelial cells to express adhesion molecules such as
ICAM-1/-2, vascular endothelial cell adhesion molecule-1
(VCAM-1) or E-selectin, in response to inflammatory
cytokines such as TNF-a, interferon-c and interleukin-1.
These adhesion molecules mediate leukocyte rolling along,
adhering to, and diapedesis through the vessel wall, and
thus have an important role in the selection of an inflam-
matory infiltrate [55].
The observation of a reduced number of infiltrated leu-
kocytes in the tumor [56] has been correlated with the fact
that tumor endothelial cells display a reduced expression of
adhesion molecules (ICAM-1 and ICAM-2) as compared
with normal endothelial cells [57, 58]. In vitro and in vivo
studies on endothelial cell anergy have demonstrated that
this reduced expression is caused by exposure to angiogenic
growth factors such as VEGF and bFGF [59]. It has been
recently described that bFGF down-regulates ICAM-1
expression via NF-jB inhibition [60]. Furthermore, we have
demonstrated that suppressed leukocyte-vessel wall inter-
actions in tumor vessels can be normalized by angiostatic
compounds, such as endostatin, angiostatin, anginex, and
16 K hPRL, as well as by treatment with chemotherapeutic
agents [61, 62]. This normalization has been correlated with
up-regulation of ICAM-1, VCAM-1, and E-selectin in
endothelial cells [44, 63]. Therefore, activation of NF-jB by
angiostatic therapy does not directly affect angiogenesis but
also has an indirect effect via expression of adhesion mol-
ecules and subsequent reversal of endothelial cell anergy.
Therefore, such activation of NF-jB resulting in stimulation
of anti-tumor immunity but also in inhibition of angiogen-
esis clearly results in an anti-tumor outcome.
Where to go from here?
Inhibition of angiogenesis is a promising therapeutic
approach to fight cancer. From several recent findings it
is likely that activation of NF-jB is a common mecha-
nism of angiostatic agents, resulting in both inhibition of
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angiogenesis and stimulation of anti-tumor immunity.
While these data raised a cautionary note about the phar-
maceutical agents that block NF-jB, they also suggest that
a targeted activation of NF-jB, specifically in endothelial
cells, could represent a new and promising strategy in
cancer treatment (Fig. 2). Further studies remain necessary
to fully understand the molecular mechanisms induced by
angiostatic agents and the role of NF-jB in endothelial
cells.
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